© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#tenofovir disoproxil fumarate

FDA Approved stamp
FDA Approves Three New, Cheaper Combination ARV Tablets
Tenofovir Disoproxil Fumarate 101
Chart of Approved and Experimental HIV Medications

Switching HIV Meds From TDF to TAF Tied to Rise in Cholesterol

Tenofovir alafenamide is an updated version of tenofovir disoproxil fumarate that is tied to better bone and kidney health.

Europe Speaks (on Covid + Hiv)

The observation that there have been Covid-19 infections in HIV+ persons on TDF/TAF argues against a complete protection from these agents.

Genetics May Drive Weight Gain After Starting an Integrase Inhibitor

Studies have found that weight gain is common after people with HIV begin an antiretroviral in this class.

Better Bone Health Markers for the New Tenofovir

Switching to new tenofovir tied to improved bone health in older people with HIV
Descovy and Truvada

Truvada Should Remain First Choice for PrEP, Experts Argue

Both Truvada and Descovy are highly effective and safe for most people taking PrEP, but the newer option has more cost barriers.

What’s the Skinny on Bone Health for People With HIV?

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Descovy and Truvada

TAF Versus TDF: What’s the Difference?

Descovy and Truvada

What’s the difference between Truvada and Descovy for PrEP?

Learn about the differences between these two HIV prevention options.

Why Do Some Newer HIV Drugs Cause Weight Gain?

Future research should examine how particular combinations of antiretrovirals contribute to weight gain, according to one expert.

Switching to New Tenofovir Tied to Improved Bone Health in Older People With HIV

Participants entered the study taking tenofovir disoproxil fumarate, and some were switched to a regimen including tenofovir alafenamide.

Biktarvy Maintains High Efficacy for Three Years in Clinical Trials

The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.

Switching to Descovy for PrEP Improves Kidney and Bone Biomarkers

However, serious kidney problems and bone fractures were rare among people taking either Descovy or Truvada for HIV prevention.

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Switching Back to Older Tenofovir Improves Lipid Levels

The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.

The International AIDS Society Conference’s Most Vital Findings

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Only Subnormal Kidney Function May Get Boost From Switch to New Tenofovir

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Advertisement
Treatment News
Newsfeed